Making decisions with real-world evidence and COVID-19
The COVID-19 pandemic has triggered intense and widespread action among the biopharma industry and...
The COVID-19 pandemic has triggered intense and widespread action among the biopharma industry and...
The rise of GLP-1 therapies and the evolution of obesity treatment Over 40% of adults in the U.S. have obesity, representing over 100 million patients.1 Not long ago, bariatric surgery was the only option for substantial weight loss among those with ...